Oncolytics Biotech (TSE:ONC) Given New C$3.50 Price Target at Raymond James

Oncolytics Biotech (TSE:ONC) had its target price hoisted by stock analysts at Raymond James from C$3.00 to C$3.50 in a report released on Friday, BayStreet.CA reports. Raymond James’ price target suggests a potential upside of 177.78% from the stock’s current price.

Oncolytics Biotech Stock Performance

ONC traded down C$0.03 on Friday, hitting C$1.26. The company had a trading volume of 58,321 shares, compared to its average volume of 54,194. Oncolytics Biotech has a 1-year low of C$1.20 and a 1-year high of C$3.10. The company’s fifty day moving average price is C$1.35 and its 200 day moving average price is C$1.42. The stock has a market cap of C$96.84 million, a price-to-earnings ratio of -3.34 and a beta of 1.38. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings results on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of C($0.10). Equities analysts predict that Oncolytics Biotech will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.